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ABSTRACT
Formalin ﬁxation and parafﬁn embedding present the
standard procedures for conserving clinical tissues for
histological analysis. However, molecular analysis is
impaired by the cross linking properties of formalin. The
PAXgene tissue system (PreAnalytix, Switzerland) is a
new formalin-free tissue collection device.
Aims In this study we aimed to evaluate this new
tissue preservation technique in comparison with
formalin ﬁxation and fresh frozen tissue samples.
Methods 12 melanoma biopsy samples were divided
and ﬁxed simultaneously with formalin, PAXgene or
fresh frozen in liquid nitrogen and analysed with regard
to morphology, immunohistochemistry, DNA and
RNA content and quality. Markers of melanocytic
differentiation and tumour cell proliferation were used.
Results Morphology was well preserved in PAXPE
samples. However, 5 out of 11 immunohistochemical
markers showed signiﬁcantly lower overall staining and
staining intensity with PAXPE tissues in comparison with
formalin-ﬁxed, parafﬁn-embedded (FFPE). Increasing
membrane permeability through adding a detergent did
proportionally increase staining intensity in PAXPE
samples. Ampliﬁcation of different mRNA amplicons
showed a direct relationship with the size of the
amplicon with greater template integrity observed in
PAXPE samples. Sequencing and mutational analysis of
DNA samples were comparable for all the different
ﬁxation methods, while the level of DNA fragmentation
seemed to be lower in PAXPE compared with FFPE
tissues.
Conclusions The switch from formalin to PAXgene
ﬁxation would require a re-evaluation of
immunohistochemical markers and staining procedures
originally developed for FFPE tissues. Our data
demonstrate that PAXPE ﬁxation offers some advantages
concerning molecular analysis. However, these
advantages would not justify substituting formalin
ﬁxation in any routine pathology laboratory.
INTRODUCTION
Formalin ﬁxation and parafﬁn embedding present
the standard procedures for conserving clinical
tissues, enabling long-term storage of human
samples. In combination with antigen retrieval
(AR) methods it enables high-quality immunohisto-
chemical analysis.1 However, the cross linking
properties of formalin cause fragmentation of
nucleic acids, impairing the quality of extracted
DNA and RNA2–4 The gold-standard for molecular
analysis remains fresh-frozen tissue, which is not
perfect for accurate histological and morphological
studies. Furthermore, the long-time storage is com-
plicated and cost-intensive.
Thus, there is a need for a ﬁxative enabling high
quality morphological and immunohistochemical,
and molecular analysis. Other important issues in
tissue preparation include ﬁxation times, tissue
shrinkage and hardening, degradation of phospho-
epitopes, handling and transport of carcinogenic
and/or ﬂammable ﬁxatives. There are alternative,
alcohol based, ﬁxatives to formalin in the market,
none of which have replaced formalin in routine
analysis up to date.5–10
The PAXgene tissue system (PreAnalytix,
Switzerland) consists of a commercially available,
easy to handle, dual-chamber tissue collection
device. According to the manufacturer’s product
description, the containers are preﬁlled with 2
reagents (PAXgene Tissue Fixation Reagent and
PAXgene Tissue Stabilisation Reagent) consisting of
methanol and acetic acid as well as a soluble
organic compound for ﬁxation and a mixture of
different alcohols including ethanol for stabilisa-
tion. The reagents are designed to preserve morph-
ology, protein content and, moreover, nucleic acid
integrity in ﬁxed tissues.
In this study we aimed to evaluate this new tissue
preservation technique in comparison with forma-
lin ﬁxation and fresh frozen tissue samples. The
preservation of morphology and the performance
in immunohistochemistry (IHC), and nucleic acid
based analysis were analysed.
MATERIAL AND METHODS
Tissue samples
12 tissue samples of primary or metastatic malig-
nant melanoma (two primary melanomas, three
lymph node metastases, and seven skin/subcutane-
ous metastases) were obtained from patients under-
going surgery at the Dermatology Department,
University hospital Zurich (table 1). Specimens
were divided into three samples immediately after
surgery and were either optimal cutting tempera-
ture compound (OCT)-embedded and snap-frozen
in liquid nitrogen, or PAXgene-ﬁxed (2–4 h ﬁxation
at 4°C) or formalin-ﬁxed (24h ﬁxation at RT).
Samples for PAXgene-ﬁxation had a maximum size
of 4×10×10mm as recommended by the manufac-
turer. The PAXgene-ﬁxed samples were transferred
into PAXgene Tissue Stabilisation Reagent for at
least 24 h at 4°C.
After dehydration of PAXgene-ﬁxed and formalin-
ﬁxed tissues, the samples were embedded either in
low melting parafﬁn for the PAX-gene-ﬁxed tissues or
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in normal parafﬁn for the formalin ﬁxed. The protocol consists of
stepwise dehydration in 70%, 96%, 100% ethanol, followed by
xylene. PAXgene-ﬁxed and formalin-ﬁxed, parafﬁn-embedded
(FFPE) tissue blocks were kept in the dark at 4°C or at room tem-
perature, respectively.
All patients gave informed consent and the study was
approved by the Ethics Committee of Zurich, Switzerland (ref-
erence number EK 800).
HISTOCHEMISTRY AND IHC ANALYSIS
H&E staining was performed according to standard procedures,
and the sections were histologically veriﬁed by two board-
certiﬁed pathologists (PN, RD). Morphology assessment
included overall morphology and nuclear, cytoplasmic and
membrane details in PAXPE and FFPE tissues.
For IHC analysis on tissues, 3 mm thick parafﬁn sections were
prepared using a rotating microtome (Microm, HM 355 S).
Sections were deparafﬁnised in xylene followed by hydration in
a graded series of ethanol (100%, 95% and 70% ethanol) and
water. Sections underwent AR pre-treatment following the spe-
ciﬁc protocol for each antibody used (see online supplementary
table 1). IHC experiments were performed using either the
DAKO autostainer plus (Glostrup, Denmark) or the Ventana
Discovery XT automatic platform (Ventana Medical System,
Tucson, Arizona, USA). To visualise immunoreactivity, anti-
mouse-horseradish peroxidase or streptavidine-alkaline-
phosphatase was added to the slides followed by either
3,3’-Diaminobenzidin (DAB) solution or fast RED solution.
Sections were counterstained and dehydrated in a graded series
of alcohol (70%, 95% and 100%), incubated in xylene and
mounted.
Antibodies against MelanA, Tyrosinase (Novocastra,
Newcastle, UK), p16 (BD, Transduction Laboratories, San Jose,
USA), Mage A4 (generous gift by Prof Giulio C. Spagnoli,
Department of Surgery, University Hospital Basel, Switzerland),
b-Raf (Abcam, Cambridge, UK), cyclinD1 (CCND1) (Epitomics/
Biocare, Concord/ Burlingame, California, USA), c-Kit (Dako,
Glostrup, Denmark), Ki67 (Dako, Glostrup, Denmark),
microphthalmia-associated transcription factor (MITF) (Dako,
Glostrup, Denmark), p53 (DAKO, Glostrup, Denmark), S100
(Ventana, Tuscon, Arizona, USA) were used as described in the
online supplementary table 1.
For Ki67 and p53, varying antibody concentrations were
applied (1 : 100, 1 : 200 and 1 : 500, 1 : 1000, respectively).
Different AR solutions administered for anti-CCND1 and
anti-p53 antibodies were pH6, pH9 and noAR (noAR). For
CCND1, MITF, and p53, staining and permeabilisation of tissue
samples was achieved by adding NP-40 0.4% solution (diluted
in PBS) for 4 min or 30 min at room temperature before the
blocking solution.
Quality of staining and scoring were assessed using an optic
microscope (Zeiss Axio Imager A1 and Axiolab). Levels of
immunoreactivity in the melanoma samples were evaluated by
pathologists using the histo-score (H-score), which calculates the
sum of the percentage of cells stained (0–100) and the staining
intensity (0–3). For example: a specimen with 10% of cells
staining 3+ (strong), 20% of cells staining 2+ (moderate), 30%
of cells staining 1+ (low) and 40% of cells unstained would
have a complete H-score of (3×10)+(2×20)+(1×30)=100.
The resulting score ranges from 0 (no staining in the tumour) to
300 (diffuse intense staining of the tumour).11 12
STATISTICAL ANALYSIS
Data were analysed by unpaired student t-test for independence.
Two groups (FFPE and PAXPE) were compared. Differences
were considered signiﬁcant when p values were ≤0.05.
NUCLEIC ACID EXTRACTIONS
Nucleic acids for each of the three tissue preservation methods
were extracted from 12 patient specimens. Total RNA was iso-
lated from each specimen with preservation speciﬁc methods
using the manufacturer’s recommended protocols. PAXPE RNA
was prepared using the PAXgene Tissue RNA Kit (PreAnalytiX
GmbH, Switzerland), and FFPE RNA was prepared using
BiOstic FFPE Tissue RNA Isolation Kit (MO BIO Laboratories
Inc., Carlsbad, California, USA.). Fresh frozen OCT embedded
tissue was washed brieﬂy with 4°C phosphate buffered saline
and RNA isolated by Trizol extraction (LifeTechnologies,
Carlsbad, California, USA). DNA was extracted from additional
sections from PAXPE and FFPE ﬁxation methods using the
BiOstic Tissue DNA Isolation Kit (MO BIO Laboratories Inc.,
Carlsbad, California, USA) using the manufacturer’s recom-
mended protocol. Extracted nucleic acids were quantiﬁed by
absorbance (Nanodrop, Thermo Scientiﬁc Inc., Wilmington,
Delaware, USA) and evaluated for impurities by 260/280 and
260/230 ratios for residual protein and chemical extraction con-
taminants respectively.
RNA AMPLIFICATION QUALITY: REVERSE TRANSCRIPTION
PCR ASSAYS (QRT-PCR)
qRT-PCR assays were designed to expose subtle differences in
the functional copy number of mRNA expressed in the sample
set. The RNA template quality as a function of preservation
method is reﬂected in the ampliﬁable target copy number.
Taqman assays were designed with nested ampliﬁcation primers
(Integrated DNA technologies Coralville Iowa, USA), and a uni-
versal taqman MGB probe (Applied Biosystems). Reactions were
performed using the Applied Biosystems (ABI) 7500 Fast
Real-Time PCR System. Resulting crossing threshold (Ct) data
were analysed and quantiﬁed with the 7500 System SDS
Software, V.1.3.1 (ABI), utilising the second derivative
maximum method.
Table 1 Patient material information
Patient’s
information Biopsy information
Patient
ID Sex
Age
(years) Tissue type Region
Primary tumour/
Metastasis
PAX01 F 64 Lymphnode Inguinal Metastasis
PAX02 M 75 Skin Back Metastasis
PAX03 M 68 Skin Shoulder Metastasis
PAX04 M 79 Skin Foot Primary tumour
PAX05 M 72 Skin Back Metastasis
PAX06 M 68 Skin Knee Metastasis
PAX07 F 61 Skin Upper
leg
Metastasis
PAX08 F 74 Subcutaneous Neck Metastasis
PAX09 M 65 Skin Front Primary tumour
PAX10 M 84 Lymphnode Inguinal Metastasis
PAX11 M 49 Skin Back Metastasis
PAX12 F 76 Lymphnode Inguinal Metastasis
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ABL1 kinase assay
ABL1 Kinase (ABL1, (NM_005157) mRNA was the target for
each of three assays designed to evaluate ﬁxation method spe-
ciﬁc preservation of a steady state transcript. ABL1 compari-
son of nucleic acid quality was performed using 2-step
RT-PCR assay chemistry designed to amplify nested frag-
ments of different lengths from the same target mRNA in
separate, parallel, reactions (ﬁgure 1B). Ampliﬁcation primers
for each of the different ABL1 RT-PCR assays are outlined in
table 2A.
First strand cDNA synthesis of ABL1 from total RNA was
generated using the target speciﬁc ABL r2 primer for each of
the assays using SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen Corp., Carlsbad, California, USA) follow-
ing the manufacturers recommended concentrations for all
reagents, and 500 ng total RNA as template in 50 μl total reac-
tion volume. RT-PCR ampliﬁcation and detection of ABL1 was
performed in MicroAmp Optical 96-well Reaction Plates (ABI).
The ﬁnal reaction volume of 25 μl using AmpliTaq Gold DNA
Polymerase with GeneAmp 10X PCR Gold Buffer (Life
Technologies Corporation, Carlsbad, California, USA), using
4.5 mM MgSO4, 50 mM 6-carboxy-X-Rhodamine (ROX) refer-
ence dye and 5 μl of the ﬁrst strand synthesis reaction as tem-
plate. RT-PCR reactions included 800 μM of each assay speciﬁc
ampliﬁcation primer (forward and reverse) and 400 μM
TaqMan-MGB 6-Carboxy-ﬂuorescine (FAM) labelled probe
ABL4. Each reaction was performed in duplicate. Thermal
cycling for detection of ABL targets in the 2-step RT-PCR
reaction used an initial denaturing incubation (95°C, 10 min)
followed by 50 cycles of PCR (20 s at 95°C, 20 s at 57°C, 90 s
at 72°C).
Tyrosinase qRT-PCR assay
Tyrosinase (TYR, NM_000372) mRNA was evaluated and nor-
malised to the stably expressed control gene ABL1 (ABL1,
(NM_005157). Nested fragments of increasing lengths for the
Figure 1 RNA Ampliﬁcation Quality RT-PCR Assays. Relative position of PCR ampliﬁcation primers and detection probes for each RT-PCR assay is
represented above the respective mRNA targets. The different coloured segments of the mRNA represent the different exons of the sequence. Figures
below the mRNA represent the ampliﬁcation products for each assay, and show the relative position on the mRNA target. This ﬁgure is only
reproduced in colour in the online version.
Table 2 RNA amplification quality assay oligonucleotides
Oligonucleotide
ID Oligo Function: Primer Sequence (5’ to 30):
(A) ABL Kinase (ABL1) RNA amplification quality assay primers
ABL203 Forward PCR Primer AGGGAGGGTGTACCATTACAGGAT
ABL207 Forward PCR Primer GCCAGTGGAGATAACACTCTAAGCA
ABL Ex2A Forward PCR Primer ACCCCAACCTTTTCGTTGC
ABL Rnew Reverse PCR Primer GCCACCGTTGAATGATGATGAACC
ABL r1 cDNA Synthesis
Primer
GCACTC CCTCAGGTAGTCCA
ABL4 Detection Probe CCTGGCCGAGTTGGTT
(B) Tyrosinase (TYR1) RNA amplification quality assay primers
TYR346-F Forward PCR Primer CGACTCTTGGTGAGAAGAAAC
TYR467-F Forward PCR Primer GGCCAAATGAAAAATGGATCA
TYR727-F Forward PCR Primer GCAGAAAAGTGTGACATTTGCAC
TYR949-F Forward PCR Primer GATGTAGAATTTTGCCTGAGTT
TYR1139-R Reverse PCR Primer CAGTAAGTGGACTAGCAAATCCTTC
PR3-3 Detection Probe CAGCTTTAGAAATACACT
ABL Rnew Reverse PCR Primer GCCACCGTTGAATGATGATGAACC
ABL r1 cDNA Synthesis
Primer
GCACTC CCTCAGGTAGTCCA
ABL4 Detection Probe CCTGGCCGAGTTGGTT
Oligonucleotides for each of the RNA amplification quality assays are listed in
separate tables. Detection probes are TaqMan MGB FAM labelled oligonucleotides.
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target mRNA were evaluated in separate parallel reactions.
Cycling conditions were optimised to attain similar qRT-PCR
ampliﬁcation efﬁciencies for each of the target speciﬁc assays.
The primer and probe sequences are listed in table 2B and the
locations are depicted in ﬁgure 1A.
QRT-PCR was performed in MicroAmp Optical 96-well
Reaction Plates (ABI). A ﬁnal reaction volume of 25 μl utilised
the SuperScript III One-Step RT-PCR System with Platinum Taq
DNA Polymerase, with a ﬁnal concentration of MgSO4 adjusted
to 5.6 mM, 20 units/reaction RNAseOUT (Invitrogen Corp.,
Carlsbad, California, USA), 50 mM ROX reference dye, and
500 ng of total RNA. Thermal cycling conditions for all
Tyrosinase RT-PCR reactions were uniform across the set of
assays. Reverse transcription incubation (54°C, 30 mi) was fol-
lowed by an initial denaturing/RT inactivation incubation (94°C,
2 min) and directly linked to 42 cycles of PCR (15 seconds at
94°C, 45 s at 62°C, and 60 seconds at 68°C).
DNA AMPLIFICATION QUALITY: REAL-TIME PCR ASSAYS
Real-time qualitative PCR assays
Qualitative real-time PCR reactions were performed on the
CFX96Real-Time PCR Detection System (Bio-Rad Laboratories,
Hercules, California, USA). Resulting crossing threshold (Ct)
data were analysed with the Bio-Rad CFX Manager Software
V.1.6, utilising the second derivative maximum method.
PCR ampliﬁcation and detection of qualitative PCR assays
was performed in Multiplate PCR Plate Low 96 Well Clear
(Bio-Rad). The ﬁnal reaction volume of 25 μl contained
Titanium Taq DNA Polymerase (Clontech Laboratories,
Mountain View, California, USA), with the manufacturers
standard buffer, 400 μM each dNTP and 1 : 104 dilution
SYBR-Green. PCR reactions were assembled with 400 nM of
each assay speciﬁc ampliﬁcation primer as described below. Each
reaction was performed in duplicate, using 25 ng DNA from the
respective specimen extractions for each reaction. Thermal
cycling for detection of each of the nested targets employed an
initial denaturing incubation (95°C, 3 min) followed by 42
cycles of PCR (20 s at 94°C, 80 s at 68°C).
BCOR DNA quality assay
BCL6 corepressor gene (BCOR, NM_001123383) sequence was
the target for each of four DNA integrity assays. The BCOR
PCR assays were designed to amplify nested fragments of differ-
ent lengths from the same target DNA in separate, parallel, reac-
tions (ﬁgure 2A). The fragment ampliﬁcation of each assay used
the same reverse primer (BCOR-R: 50-ACTGACCCTGAAA
CGTTAGTGATG-30) paired with forward primers for each of
the different BCOR amplicons (table 3).
CACNG4 DNA quality assay
Calcium channel, voltage-dependent, gamma subunit 4 gene
(CACNG4, NM_014405) sequence was the target for each of
three DNA integrity assays. The CACNG4 PCR assays were
designed to amplify nested fragments of different lengths from
Figure 2 DNA quality RT-PCR and Sequencing Assays. Fragments of genomic DNA targets are represented with relative positions of ampliﬁcation
primers (black arrows) above the DNA fragment. The different amplicons for each assay are represented below the DNA fragment, to show the
position of the different amplicons relative to the DNA target as well as their relative position and overlap to each other. This ﬁgure is only
reproduced in colour in the online version.
Table 3 PCR amplified DNA fragments and primers
Sequenced
fragment
assay ID
Amplicon
length
(bp)
Forward
primer ID
Forward primer sequence
(50 to 30):
BCOR-949 949 BCOR-949F TCTACCTGCCGCCACCTC
BCOR-553 553 BCOR-553F TGACAGTTAGCAGCGAGTTCC
BCOR-275 275 BCOR-275F AGGGCTGGAAGTGGCTTAGT
BCOR-145 145 BCOR-145F GCTGAATCAAATGATGGCAAAGTT
CACNG4-571 571 CACNG4-571R CATCCTGTGTGACAAAAAGAGC
CACNG4-277 277 CACNG4-277R CCTCGGTGGACCTTGAGC
CACNG4-117 117 CACNG4-117R CACGGTCTCAGCCACAA
PCR amplified DNA fragments, as depicted in figure 2, used for PCR analysis of
oligonucleotide fragmentation and sequencing quality analysis and the DNA
oligonucleotides that are specific to PCR amplification and sequencing of each
fragment. Unique oligonucleotide primers for sequencing BCOR gene fragments
generate sequence in the forward direction. Unique oligonucleotide primers for the
CACNG4 gene fragments generate sequence in the reverse direction.
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the same target DNA in separate, parallel, reactions (ﬁgure 2B).
The fragment ampliﬁcation of each assay used the same forward
primer (CACNG4-F: 50-ATTTCCAGCAACACAGGTGACC-30)
paired with reverse primers for each of the different CACNG4
amplicons (table 3).
SANGER SEQUENCING ASSAYS
To evaluate the effect of the tissue preservation method on
sequencing quality, ampliﬁed fragments from each patient speci-
men and for each fragmentation assay amplicon (each of four
BCOR amplicons and three CACNG4 amplicons) were used for
DNA sequencing analysis. Each of the 25 μl PCR reactions used
for sequencing were diluted with 75 μl nuclease free water and
transferred to individual wells of Multiscreen PCR μ96 Filter
Plate (Millipore, Billerica, Massachusetts, USA). PCR ampliﬁed
products were isolated by ﬁltration under vacuum and resu-
pended with 20 μl nuclease free water.
The puriﬁed PCR products of each BCOR or CACNG4 reac-
tion were bi-directionally sequenced using each ampliﬁcation
primer with ABI Big Dye V.3.1 Terminator Cycle Sequencing
Kit. Dye terminator reactions were puriﬁed using Millipore
Montage PCRu96 Filter Plate (Millipore, Billerica,
Massachusetts, USA) and the sequences resolved by capillary
electrophoresis using an ABI 3730xl DNA Analyser (Applied
Biosystems, Foster City, California, USA).
RESULTS
Morphology and IHC comparison with different ﬁxation
methods
In order to investigate the conservation of morphological
characteristics under PAXgene-ﬁxation, H&E staining of
PAXgene-ﬁxed, parafﬁn-embedded (PAXPE) and FFPE speci-
mens were evaluated in parallel. The morphology was well
preserved in PAXPE specimens. No evident differences in com-
parison with FFPE tissues could be detected (ﬁgure 3).
For the purpose of comparing protein immunoreactivity
between PAXPE and FFPE samples, IHC for 10 different anti-
gens was performed using protocols previously established for
FFPE. Markers of melanocytic differentiation such as S100,
MITF, Tyrosinase and MelanA, as well as markers of tumour
cell proliferation such as ki67, CCND1, p16 and p53 were
investigated for staining intensity.
Using IHC protocols established for FFPE, staining as well as
counterstaining was found to be generally stronger in FFPE
compared with PAXPE tissues (ﬁgures 3 and 4, see online sup-
plementary table S2). By evaluating the 12 patient samples for
immunoreactivity, a signiﬁcant difference between FFPE and
PAXPE ﬁxated tissues could be shown for b-Raf, MITF,
CCND1, Tyrosinase, and MAGE-4 staining, which were signiﬁ-
cantly lower in PAXPE tissues. For S100 immunoreactivity, no
difference between FFPE and PAXPE tissues could be detected.
A moderate reduction in staining intensity was seen in PAXPE
tissues compared with FFPE tissues for c-Kit, Ki67, p53, p16
and MelanA staining. However, these differences in intensity
were not statistically signiﬁcant (ﬁgure 4).
Whereas the signal intensity for Ki67 in PAXPE material
could be increased by increasing the antibody concentration,
staining intensity for p53 in PAXPE material could not be
increased by increasing the antibody concentration (data not
shown). Moreover, using anti-CCND1 and anti-p53 antibodies,
different AR solutions were tested, but could not improve the
staining signal (data not shown).
In order to facilitate nuclear staining, membrane permeability
was increased using NP-40 in PAXPE tissues before adding
MITF, p53, or CCND1 antibody. Staining increased proportion-
ally with increasing membrane permeability in PAXPE tissues
(ﬁgure 5).
In summary, IHC protocols established for FFPE tissues
cannot be applied unmodiﬁed to PAXPE tissues since these
seem to require different conditions.
NUCLEIC ACID QUALITY AS A FUNCTION OF FIXATION
METHOD
To investigate the relative quality of nucleic acids from each
tissue preservation method, RNA and DNA were extracted from
each of the specimens. Total RNA and DNAwere separately iso-
lated from serial sections for each specimen with preservation
speciﬁc methods using each manufacturer’s recommended pro-
tocols. Extracted nucleic acids were quantiﬁed by absorbance
and evaluated for impurities by 260/280 and 260/230 ratios for
residual protein and chemical extraction contaminants respect-
ively. Sample yield varied by cross-sectional tissue area and
number of sections extracted. Since not all sections were slide
mounted prior to extraction, yield per sectional area could not
be calculated. Preservation method speciﬁc extraction methods
did not show signiﬁcant differences in sample purity as mea-
sured by 260/280 and 260/230 ratios (table 4). Performance
effects based on co-puriﬁcation of inhibitors that exhibit absorb-
ance in these wavelengths was not observed at signiﬁcant levels
likely to exert negative effects on the nucleic acid performance
in the assessment assays.
RNA QUALITY ASSESSMENT BY REVERSE TRANSCRIPTION
PCR ASSAYS
To evaluate the RNA template quality as a function of the pres-
ervation method, qRT-PCR assays were designed to identify dif-
ferences in the ampliﬁable copy number of the ABL1 kinase
stable house-keeping gene, and a second transcript known to be
variably expressed in malignant melanoma, Tyrosinase. RNA
template quality was evaluated using both a 2-step cDNA syn-
thesis followed by PCR, and a single tube 1-step method.
QRT-PCR reactions were evaluated for each method using
Real-Time PCR, and the resulting data analysed and quantiﬁed
utilising the second derivative maximum method.
ABL1 kinase assay
ABL1 Kinase (ABL1, (NM_005157) mRNA was chosen as the
target sequence for house-keeping gene expression. Three over-
lapping ABL1 amplicons were used for comparison of nucleic
acid quality with 2-step RT-PCR chemistry. The assays were
designed to amplify nested fragments, of increasing lengths
from the same target mRNA in parallel reactions (ﬁgure 1B).
Ampliﬁcation primers for each of the different ABL1 RT-PCR
assays are outlined in table 2.
Synthesis of ABL1 cDNA from total RNA was generated
using the target speciﬁc primer ABL r2 primer for all of the
assays. The ABL1 assays showed a strong trend toward higher
integrity of template with the PAXPE samples over the FFPE
samples. The level of expression varied between individual
samples while the trend of greater ampliﬁcation of the smallest
fragments and less ampliﬁcation of larger fragments correlated
across all samples. For the ABL1 target ampliﬁcation of the
largest fragment (806 bp) failed to amplify for both ﬁxation
methods (ﬁgure 6).
Tyrosinase assay
Tyrosinase (TYR, NM_000372) mRNA expression levels were
normalised to the 114 bp assay for the control gene ABL1 using
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high quality in-tact RNA isolated from a melanoma cell line. To
assess the quality of each preservation method, a series of
increasing length one-step RT-PCR assays were designed to
amplify nested fragments from the same target mRNA in paral-
lel reactions. The quality of template preservation as it pertains
to ampliﬁable length of RNA is reﬂected in the ampliﬁable
target copy number as measured by the crossing threshold. To
be able to compare the results between different length assays,
the oligonucleotide primers and reaction conditions were opti-
mised to attain similar qRT-PCR ampliﬁcation efﬁciencies. The
sequences are listed in table 2B and the locations are graphically
depicted in ﬁgure 1A.
The quality between clinical isolates varies signiﬁcantly which
likely arises from the differences between the tumour material
and processing time, precluding the ability to compare absolute
values between clinical isolates. However, assays of increasing
length evaluated within a speciﬁc tumour for each of the ﬁx-
ation methods shows a clear trend for greater template integrity
in the PAXPE tissues relative to FFPE tissues (ﬁgure 7). In these
assays additional intermediate size targets were generated
Figure 3 Comparison of H&E and immunohistochemistry staining in corresponding formalin-ﬁxed, parafﬁn-embedded and PAXPE tissues. This
ﬁgure is only reproduced in colour in the online version.
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indicating available target template up to 712 bases in some
samples. Although PAXPE ﬁxed tissues exhibit signiﬁcantly
higher amounts of the larger amplicons, limitations of fragments
larger than 500 bases are observed in most samples.
DNA QUALITY ASSESSMENT BY PCR AMPLIFICATION
AND DIRECT SEQUENCING
Qualitative real-time PCR reactions were performed using non-
speciﬁc double stranded DNA binding dye Sybr-green. Resulting
data were analysed utilising the second derivative maximum
method. Duplicate reactions using low amounts of template
(25 ng) from each of the ﬁxation methods were used to empha-
sise any differences in sample quality. Two target genes known
not to vary in copy number in melanoma were chosen to avoid
potential variation between clinical isolates.
DNA ampliﬁcation assay
Assays were designed to amplify a series of nested fragment
lengths, from the same target DNA in parallel reactions (ﬁgure 2).
Similar to assays designed for examining the integrity of the RNA,
ampliﬁcation of each DNA target sequence utilised a common
reverse primer paired with forward primers to generate a series of
increasing size amplicons as depicted in table 3.
A dramatic loss of integrity was observed with the DNA amp-
liﬁcation proﬁles for the BCOR and CACNG4 genes. The amp-
liﬁcation of increasing size fragments are of measurably higher
integrity in PAXPE tissues compared with FFPE. Both target
genes exhibit the same trend across all samples. Specimens 11
and 12 were of notably less integrity for both paxgene-ﬁxed,
parafﬁn-embedded (PAXPE) and FFPE specimens, presumably a
result of pre-ﬁxation handling (ﬁgure 8).
Sequencing analysis
To evaluate the effect of the tissue preservation method on
sequencing quality, ampliﬁed fragments from each patient speci-
men, for each fragmentation assay amplicon (each of four
BCOR amplicons and three CACNG4 amplicons) were used as
template for DNA sequencing analysis.
The puriﬁed PCR products of each BCOR or CACNG4
reaction were sequenced in both directions and analysed for
Figure 5 Increase of nuclear staining
under NP-40 treatment of PAXPE
tissues in comparison with the
corresponding formalin-ﬁxed,
parafﬁn-embedded tissue. This ﬁgure is
only reproduced in colour in the online
version.
Figure 4 Comparison of staining intensity in corresponding formalin-ﬁxed, parafﬁn-embedded and PAXPE tissues.
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sequencing quality and read length. Since PCR was allowed to
cycle to plateau the differences in ampliﬁcation resulting from
reduced copy number were compensated by extensive ampliﬁca-
tion. No signiﬁcant difference in read length or sequence
quality was observed to correlate with amplicon length (data
not shown).
DISCUSSION
Formalin ﬁxation and parafﬁn embedding has been the standard
routine procedure for preservation of human specimens for
decades. Stored tissues in pathology department archives
present an important resource for future detailed clinical and
molecular analysis of diseases. Formalin enables cost-effective
long-term storage of human samples and preserves detailed cel-
lular morphology. However, formalin ﬁxation leads to cross-
linking of proteins as well as fragmentation of nucleic acids,
impairing the quality of extracted proteins as well as RNA and
DNA.5 13 14 The formalin-free PAXgene tissue system was
designed to improve the quality of molecular analysis without
diminishing the quality of histopathological analysis.
Concerning morphological analysis, morphology was well
preserved in PAXPE samples. H&E staining revealed no differ-
ences between FFPE and PAXPE tissues concerning tissue archi-
tecture, cellular and nuclear morphology, apart from a slightly
stronger staining in FFPE tissues. Higher eosinophilia was not
observed in our samples, in contrast to the study reported by
Kap et al.15 This difference might be due to the different tissue
types used. Difﬁculties in tissue handling as described for other
formalin-free, alcohol and acid based ﬁxatives such as tissue
hardening or softening, tissue shrinkage, pigment deposition,
and lysis of erythrocytes were not observed.6 The good mor-
phological results of PAXPE in comparison with other studies
conducted on formalin-free ﬁxatives may be attributed in part
to the small size of tissue samples (4×10×10 mm as suggested
by the manufacturer), the resulting short ﬁxation time of 2–4 h,
and the tissue type used (melanoma samples from skin and
lymph nodes).
Immunohistochemical analysis revealed a generally lower
counterstaining in PAXPE tissues compared with FFPE material.
Depending on immunohistochemical marker tested, signiﬁcant
Table 4 Spectrophotometric measurement of extracted nucleic acids
Patient (specimen) ID: Tissue fixation Extraction method
RNA Extractions DNA Extractions
A260 A280 A260/280 A260/230 A260 A280 A260/280 A260/230
P1 PaxGene PreAnalytix 1.67 0.82 2.02 1.58 2.23 1.17 1.90 2.51
Formalin MoBio 0.47 0.23 2.00 1.89 0.23 0.11 2.06 2.06
Frozen Trizol 0.68 0.35 1.94 1.20
P2 PaxGene PreAnalytix 3.19 1.57 2.03 1.96 3.27 1.62 2.02 2.38
Formalin MoBio 1.59 0.77 2.06 2.03 0.12 0.04 3.23 1.55
Frozen Trizol 2.41 1.20 2.00 1.86
P3 PaxGene PreAnalytix 2.64 1.32 2.00 1.50 6.16 3.18 1.94 2.40
Formalin MoBio 10.13 4.92 2.06 2.12 14.71 7.38 1.99 2.26
Frozen Trizol 5.87 3.02 1.94 1.33
P4 PaxGene PreAnalytix 0.93 0.46 2.02 0.56 4.77 2.44 1.96 2.30
Formalin MoBio 4.65 2.37 1.96 1.78 9.13 4.67 1.96 2.25
Frozen Trizol 7.65 4.14 1.85 1.07
P5 PaxGene PreAnalytix 0.72 0.40 1.81 0.56 4.41 2.90 1.52 0.93
Formalin MoBio 2.58 1.34 1.93 1.55 2.31 1.23 1.88 1.76
Frozen Trizol 1.64 0.95 1.73 0.69
P6 PaxGene PreAnalytix 0.51 0.28 1.81 0.36 1.57 0.82 1.93 2.35
Formalin MoBio 2.00 1.04 1.93 0.89 1.43 0.71 2.01 2.14
Frozen Trizol 1.73 0.96 1.79 0.81
P7 PaxGene PreAnalytix 0.69 0.35 1.96 1.39 3.95 1.97 2.01 2.24
Formalin MoBio 7.64 3.92 1.95 1.91 22.32 11.15 2.00 2.22
Frozen Trizol 0.90 0.52 1.74 0.63
P8 PaxGene PreAnalytix 1.70 0.82 2.06 1.95 3.75 1.86 2.02 2.29
Formalin MoBio 5.82 2.98 1.95 1.58 13.73 6.89 1.99 2.25
Frozen Trizol 3.19 1.67 1.91 1.03
P9 PaxGene PreAnalytix 4.52 2.18 2.07 0.69 2.80 1.38 2.04 0.41
Formalin MoBio 7.89 3.97 1.99 1.76 12.65 6.27 2.02 2.13
Frozen Trizol 6.59 4.04 1.63 0.82
P10 PaxGene PreAnalytix 2.14 1.05 2.04 0.85 5.74 2.89 1.99 2.32
Formalin MoBio 3.69 1.86 1.99 0.85 11.35 5.70 1.99 2.23
Frozen Trizol 3.35 1.70 1.98 1.37
P11 PaxGene PreAnalytix 4.94 2.41 2.05 0.86 15.62 7.90 1.98 2.22
Formalin MoBio 3.97 1.99 1.99 1.68 2.34 1.20 1.96 0.48
Frozen Trizol 2.79 1.42 1.97 1.56
P12 PaxGene PreAnalytix 0.93 0.47 1.98 0.62 3.79 1.83 2.07 2.25
Formalin MoBio 3.16 1.62 1.96 1.97 6.87 3.44 1.99 2.27
Frozen Trizol 19.24 12.13 1.59 0.84
DNA and RNA were extracted from different portions of the same specimens from each of the preservation methods. Limited size of specimens did not allow for extraction of DNA from
frozen specimens. Absorbance of each extracted sample was measured by spectrophotometer (Nanodrop ND1000) and nucleic acid sample purity assessed by ratios of absorbance 260
nm/280 nm (A260/280) and absorbance 260 nm/230 nm (A260/230). A260/280 of ∼1.8, or greater, is generally accepted as ‘pure’ for DNA; A260/280 of ∼2.0 is generally accepted as
‘pure’ for RNA. If the ratio is appreciably lower in either case, it may indicate the presence of protein or other contaminants that absorb strongly at or near 280 nm. If the A260/280
value is appreciably lower than ∼2.0–2.2, it may indicate the presence of residual organic contaminants which absorb at 230 nm.
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differences in staining intensity could be detected. 5 out of 11
markers showed signiﬁcantly lower overall staining with PAXPE
tissues in comparison with FFPE. Increasing antibody concentra-
tion could improve staining intensity for some markers in
PAXPE tissues but not for all. Pre-treatment with different AR
methods, in order to unmask antigen epitopes by enzymatic pre-
digestion, as well as noAR, did not improve staining quality of
PAXPE tissues. However, increasing membrane permeability
through adding a detergent did proportionally increase staining
intensity of nuclear markers in PAXPE samples. The present
study shows that immunohistochemical protocols developed for
FFPE tissues require extensive optimisation and validation
before being used for PAXPE tissues. A recently published study
demonstrated successful extraction of non-degraded and immu-
noreactive protein for downstream applications such as western
blotting reverse-phase protein microarrays.5 Results of the
immunohistochemical analysis were recently reported by Kap
et al.15 The authors report, only a few IHC antibodies exhibited
lower levels of immune reactivity which could be overcome by
omittingAR, adjusting antibody concentration, or using another
clone. However, the authors only present single case examples
and do not provide validated scoring results or statistics.
Concerning other studies performed with formalin-free,
alcohol and acid based ﬁxatives, a reduction of staining intensity
and quality was observed, depending on the markers used.6
For RNA analysis, the ampliﬁcation of different mRNA
amplicons showed signiﬁcant differences between PAXPE and
FFPE samples. FF, which presents the intact template, was sig-
niﬁcantly better. This data is consistent with previous reports of
Ergin et al and Viertler et al. The authors report ampliﬁcation
of longer amplicons from PAXPE and FF samples, whereas for
FFPE only shorter amplicons could be ampliﬁed.5 16
Figure 6 RNA Ampliﬁcation Quality Assay—ABL Tyrosine Kinase Assay. The ﬁgure shows the calculated data and graphed results. The graphically
depicted data has been divided into two separate graphs with different scales for the relative ampliﬁcation values to make all the lower expression
values more visible. Data is assigned to the respective graphs according to the maximum ampliﬁcation value within a patient sample set.
Ampliﬁcation quality is calculated as a 2−DCt value (DCt=Ct (experimental RNA)—Ct (control RNA)) to allow comparison of ampliﬁcation quality scores on a
linear scale. The ampliﬁcation of each length of ABL1 is measured relative to ampliﬁcation of the same ABL1 amplicon from control RNA extracted
from cultured cells. Amplicons with 2−DCt values close to 1.0 indicate that the target, from the respective RNA sample, is close to being fully in-tact.
2−DCt approaching zero for demonstrate greater degradation of the target in the experimental RNA sample. This ﬁgure is only reproduced in colour
in the online version.
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For DNA analysis, sequencing and mutational analysis are
comparable for all the different ﬁxation methods, while the
level of DNA fragmentation seems to be lower in PAXPE com-
pared with FFPE tissues. The extensive ampliﬁcation of target
template during the PCR step of sequencing masks the differ-
ences in copy number. These differences are however observed
in the comparative analysis of DNA quality and target fragment
content using real-time PCR with Sybr-green(TM). Fixation spe-
ciﬁc extraction methods further complicate the observed differ-
ences in template quality. Analysis of both RNA and DNA
derived from PAXgene tissue suggest that it may be useful for
assays that span greater fragment length such as translocation
events. Larger ampliﬁable fragments could also reduce the
number of individual reactions required to span larger exons or
for nextgen sequencing of mutations to determine whether clin-
ically relevant mutations are found in cis or trans to one
another.
Although the PAXgene ﬁxative displays improved preserva-
tion of nucleic acids, the switch from formalin to PAXgene
ﬁxation would require a re-evaluation of markers and stain-
ing procedures because protocols as well as information
regarding sensitivity and speciﬁcity have been obtained using
formalin-ﬁxed samples. Furthermore, preservation of
morphological as well as molecular features after prolonged
storage (eg, 10 years) of PAXPE tissues needs still to be
evaluated.
The small sample size of 4×10×10 mm for PAXgene ﬁxation
is a major limit to application in routine pathology, since most
surgical specimens are of bigger sizes. The associated costs of
this ﬁxation system are a multiple compared with inexpensive
formalin, and need to be taken into account, as well as the
necessary logistics, such as the recommended storage of PAXPE
blocks at 4°C compared with room temperature for FFPE, when
selecting a ﬁxative for routine pathology. However, when using
small sample sizes, ﬁxation times of only 2–4 h using PAX gene
compared with 24 h using formalin can facilitate and accelerate
workﬂow in laboratories. Furthermore, carcinogenic effects of
formalin in laboratory personnel could be more easily avoided
by creating a formalin-free environment, but with the addition
of handling toxic and highly inﬂammable methanol-containing
substances.
Our data demonstrate that PAXPE ﬁxation offers some key
advantages in nucleic acid detection that may be useful for spe-
ciﬁc disease linked markers that require longer amplicon ana-
lysis. Currently, for routine pathology laboratory work, we
recommend continuing to use FFPE ﬁxation.
Figure 7 RNA Ampliﬁcation Quality—Tyrosinase Assay. The table and graph show the same data. The ampliﬁcation of each length of TYR is
measured relative to ampliﬁcation of a control ABL1 fragment (114 bp) from the same RNA cell line. Ampliﬁcation quality is calculated as a 2−DCt
value (DCt=Ct (TYR amplicon)—Ct (ABL1 control)) to allow for comparing ampliﬁcation quality scores on a linear scale. Amplicons with 2
−DCt values close
to 1.0 show that the target, from the respective RNA sample, is close to being fully in-tact. 2−DCt approaching zero for demonstrate greater
degradation of the target in the experimental RNA sample. This ﬁgure is only reproduced in colour in the online version.
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Take home messages
▸ In PAXPE samples, morphology is well preserved but
immunohistochemistry requires re-evaluation of markers and
staining procedures.
▸ PAXPE samples provide greater template integrity of mRNA
amplicons than formalin-ﬁxed, parafﬁn-embedded samples.
▸ DNA fragmentation seems to be lower in PAXPE samples
compared with formalin-ﬁxed, parafﬁn-embedded samples.
▸ The authors would not suggest substituting formalin ﬁxation
with PAXgene ﬁxation in a routine pathology laboratory.
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